HPGD and type 2 diabetes mellitus: The current study is the first comprehensive examination of the mechanistic impacts of SW033291 on T2DM by combining liver transcriptomics and liver/serum metabolomics, which is important for the future development of SW033291 or other 15-PGDH inhibitors for clinical use.